Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Date
2022
Author
Can, Pelin Kuteyla
ALPSOY, ERKAN
Atakan, Nilgun
ENGİN, BURHAN
Hasal, Eda
Kocaturk, Emek
BÜLBÜL BAŞKAN, EMEL
SU KÜÇÜK, ÖZLEM
Ozdemir, Mustafa
Ornek, Sinem
Metadata
Show full item record
Abstract
Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.
URI
http://hdl.handle.net/20.500.12627/185770
https://doi.org/10.1016/j.abd.2022.03.003
Collections